Compare SUPN & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUPN | BHC |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2012 | N/A |
| Metric | SUPN | BHC |
|---|---|---|
| Price | $51.67 | $5.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $61.60 | $8.67 |
| AVG Volume (30 Days) | 754.8K | ★ 2.2M |
| Earning Date | 02-24-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.97 |
| Revenue | $681,539,000.00 | ★ $10,029,000,000.00 |
| Revenue This Year | $8.18 | $6.81 |
| Revenue Next Year | $22.15 | $4.11 |
| P/E Ratio | ★ N/A | $6.08 |
| Revenue Growth | 4.54 | ★ 5.86 |
| 52 Week Low | $29.16 | $4.25 |
| 52 Week High | $57.65 | $8.69 |
| Indicator | SUPN | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 34.44 |
| Support Level | $47.29 | $5.62 |
| Resistance Level | $49.71 | $5.85 |
| Average True Range (ATR) | 1.40 | 0.20 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 100.00 | 19.35 |
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.